ARRONAX, a high-energy and high-intensity cyclotron for nuclear medicine

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 35, Issue 7, 2008, Pages 1377-1387

  Haddad, Ferid ^a   Ferrer, Ludovic ^a,b   Guertin, Arnaud ^a   Carlier, Thomas ^a   Michel, Nathalie ^a   Barbet, Jacques ^a   Chatal, Jean François ^a  

^a UNIVERSITÉ DE NANTES   (France)

^b CENTRE RENÉ GAUDUCHEAU   (France)

Author keywords

Cyclotron; Dosimetry; Positron emission tomography (PET); Radionuclides; Targeted radionuclide therapy

Indexed keywords

ASTATINE 211; COBALT; COBALT 55; COPPER 64; COPPER 67; GALLIUM 68; IODINE 124; IRON 52; RADIOISOTOPE; RUBIDIUM 82; SCANDIUM; SCANDIUM 44; SCANDIUM 47; YTTRIUM 86;

ALPHA RADIATION; ARTICLE; CYCLOTRON; DOSIMETRY; ELECTRON; ENERGY RESOURCE; FRANCE; HALF LIFE TIME; ISOTOPE LABELING; NONHUMAN; NUCLEAR MEDICINE; POSITRON EMISSION TOMOGRAPHY;

ALPHA PARTICLES; BETA RAYS; CYCLOTRONS; EQUIPMENT DESIGN; FRANCE; HALF-LIFE; HUMANS; NUCLEAR MEDICINE; NUCLEAR PHYSICS; POSITRON-EMISSION TOMOGRAPHY; RADIOISOTOPES; RADIOPHARMACEUTICALS;

EID: 45049085785     PISSN: 16197070     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-008-0802-5     Document Type: Article

References (85)

1. Pentlow KS, Graham MC, Lambrecht RM, Cheung NK, Larson SM. Quantitative imaging of I-124 using positron emission tomography with applications to radioimmunodiagnosis and radioimmunotherapy. Med Phys 1991;18(3):357-66. May-Jun.
2. DeNardo SJ, DeNardo GL, Kukis DL, Shen S, Kroger LA, DeNardo DA, et al. 67Cu-2IT-BAT-Lym-1 pharmacokinetics, radiation dosimetry, toxicity and tumour regression in patients with lymphoma. J Nucl Med 1999;40(2):302-10, Feb.
3. 124I PET and 3-dimensional-internal dosimetry (3D-ID) software. J Nucl Med 2004;45(8):1366-72. Aug.
4. Barbet J, Chatal JF, Gauche F, Martino J. Which radionuclides will nuclear oncology need tomorrow? Eur J Nucl Med Mol Imaging 2006;33(6):627-30, Jun.
5. Shankar LK, Hoffman JM, Bacharach S, Graham MM, Karp J, Lammertsma AA, et al. Consensus recommendations for the use of 18F-FDG PET as an indicator of therapeutic response in patients in National Cancer Institute Trials. J Nucl Med 2006;47:1059.
6. Verel I, Visser GW, van Dongen GA. The promise of immuno-PET in radioimmunotherapy. J Nucl Med 2005;46:164S-71S.
7. Lee FT, Scott AM. Immuno-PET for tumor targeting. J Nucl Med 2003;44:1282-3.
8. Goldenberg DM, Sharkey RM. Advances in cancer therapy with radiolabeled monoclonal antibodies. Q J Nucl Med Mol Imaging 2006;50(4):248-64, Dec.
9. de Jong M, Kwekkeboom D, Valkema R, Krenning EP. Radiolabelled peptides for tumour therapy: current status and future directions. Plenary lecture at the EANM 2002. Eur J Nucl Med Mol Imaging 2003;30(3):463-9, Mar.
10. Goldenberg DM, Sharkey RM, Paganelli G, Barbet J, Chatal JF. Antibody pretargeting advances cancer radioimmunodetection and radioimmunotherapy. J Clin Oncol 2006;24(5):823-34. Feb 10.
11. Kolsky KL, Joshi V, Mausner LF, Srivastava SC. Radiochemical purification of no-carrier-added scandium-47 for radioimmunotherapy. Appl Radiat Isot 1998;49:1541-49.
12. DeNardo GL, DeNardo SJ, Kukis DL, O'Donnell RT, Shen S, Goldstein DS, et al. Maximum tolerated dose of 67-Cu-2IT-BAT-LYM1 for fractionated radioimmunotherapy of non-Hodgkin's lymphoma: a pilot study. Anti Cancer Res 1998;18:2779-88.
13. 124I. Phys Med Biol 2004;49:5505.
14. Williams HA, Robinson S, Julyan P, Zweit J, Hastings D. A comparison of PET imaging characteristics of various copper radioisotopes. Eur J Nucl Med 2005;32:1473.
15. 67/64Cu-labeled anti-L1-CAM antibody chCE7: selection of copper ligands and PET imaging. Nucl Med Biol 2003;30:417.
16. Philpott GW, Schwarz SW, Anderson CJ, Dehdashti F, Connett JM, Zinn ZR, et al. RadioimmunoPET: detection of colorectal carcinoma with positron-emitting copper-64-labeled monoclonal antibody. J Nucl Med 1995;36:1818.
17. Shen S, DeNardo GL, DeNardo SJ, Salako Q, Morris G, Banks D, et al. Dosimetric evaluation of copper-64 in copper-67-2IT-BAT-Lym-1 for radioimmunotherapy. J Nucl Med 1996;37:146.
18. Dearling JL, Lewis JS, Mullen GE, Rae MT, Zweit J, Blower PJ. Design of hypoxia-targeting radiopharmaceuticals: selective uptake of copper-64 complexes in hypoxic cells in vitro. Eur J Nucl Med 1998;25:788.
19. 60/61/62/64Cu-ATSM: a hypoxia imaging agent for PET. Eur J Nucl Med 2005;32:764.
20. 68Ga-DOTATOC: preliminary data. Eur J Nucl Med 2001;28:1751.
21. Smith-Jones PM, Stolz B, Bruns C, Albert R, Reist HW, Fridrich R, et al. Gallium-67/gallium-68-[DFO]-octreotide-a potential radiopharmaceutical for PET imaging of somatostatin receptor-positive tumors: synthesis and radiolabeling in vitro and preliminary in vivo studies. J Nucl Med 1994;35:317.
22. 68Ga-DOTA-D-Phe1-Tyr3- octreotide kinetics in patients with meningiomas. J Nucl Med 2005;46(Suppl):763.
23. Klivonyi G, Schuhmacher J, Patzelt E, Hauser H, Matys R, Moock M, et al. Gallium-68 chelate imaging of human colon carcinoma xenografts pretargeted with bispecific anti-CD44V6/anti-gallium chelate antibodies. J Nucl Med 1998;39:1769.
24. Schuhmacher J, Kaul S, Klivonyi G, Junkermann H, Magener A, Henze M, et al. Immunoscintigraphy with positron emission tomography: gallium-68 chelate imaging of breast cancer pretargeted with bispecific anti-MUC1/anti-Ga chelate antibodies. Cancer Res 2001;61:3712.
25. Sanchez-Crespo A, Andreo P, Larsson SA. Positron flight in human tissues and its influence on PET image spatial resolution. Eur J Nucl Med Mol Imaging 2004;31:44.
26. 68Ga-labeled peptides in tumor imaging. J Nucl Med 2005;46(Suppl):172S.
27. Shea MJ, Wilson RA, deLandsheere CM, Deanfield JE, Watson IA, Kensett MJ, et al. Use of short and long-lived rubidium tracers for the study of transient ischemia. J Nucl Med 1987;28:989.
28. Anonymous. The strontium-82/rubidium-82 generator. Int J Rad Appl Instrum 1987;38(3):171-239.
29. Erdi Y, Macapinlac H, Larson S, Erdi A, Yeung H, Furhang E, et al. Radiation dose assessment for I-131 therapy of thyroid cancer using I-124 PET imaging. Clin Positron Imaging 1999;2:41.
30. Eschmann MS, Reischl G, Bilger K, Kupferschleger J, Thelen MH, Dohmen BM, et al. Evaluation of dosimetry of radioiodine therapy in benign and malignant thyroid disorders by means of iodine-124 and PET. Eur J Nucl Med Mol Imaging 2002;29:760-7.
31. Kenanova V, Olafsen T, Crow DM, Sundaresan G, Subbarayan M, Carter NH, et al. Tailoring the pharmacokinetics and positron emission tomography imaging properties of anti-carcinoembryonic antigen single-chain Fv-Fc antibody fragments. Cancer Res 2005;65:622.
32. 124I-labeled engineered anti-CEA minibodies and diabodies allow high-contrast, antigen-specific small-animal PET imaging of xenografts in athymic mice. J Nucl Med 2003;44:1962.
33. 124I-CDR-grafted humanized A33 monoclonal antibody. J Nucl Med 2001;42:764.
34. 124I-annexin V and PET. Nucl Med Biol 2005;32:395.
35. Robinson MK, Doss M, Shaller C, Narayanan D, Marks JD, Adler LP, et al. Quantitative immuno-positron emission tomography imaging of HER2-positive tumor xenografts with an iodine-124 labeled anti-HER2 diabody. Cancer Res 2005;65:1471.
36. Shaul M, Abourbeh G, Jacobson O, Rozen Y, Laky D, Levitzki A, et al. Novel iodine-124 labeled EGFR inhibitors as potential PET agents for molecular imaging in cancer. Bioorg Med Chem 2004;12:3421.
37. IAEA. Optimization of production and quality control of therapeutic radionuclides and radiopharmaceuticals. IAEA-TECDOC-1114 1999. Vienna: IAEA; 1999.
38. Sachdev DR, Yaffe L. Isomer ratios for the 44Ca(p,n)44m,gSc and 85Rb(p,n)85m,gSr reactions. Can J Phys 1969;47:1667.
39. Kurfess JD, Phlips BF (2001) Coincident Compton nuclear medical imager. In: Proceedings of the IEEE Nuclear Science Symposium conference, San Diego, California.
40. Kurfess JD, Johnson WN, Kroeger RA, Phlips BF, Wulf EA. Timing methods for depth determination in germanium strip detectors. Nucl Instr Meth A 2003;505:178.
41. Heppeler A, Froidevaux S, Eberle AN, Maecke HR. Receptor targeting for tumor localisation and therapy with radiopeptides. Curr Med Chem 2000;7:971.
42. 86YDOTA-DPhe1- Tyr3-octreotide (86YSMT487) using positron emission tomography in non-human primates and calculation of radiation doses of the 90Y-labelled analogue. Eur J Nucl Med 1999;26:358.
43. Lundqvist H, Lubberink M, Tolmachev V, Lovqvist A, Sundin A, Beshara S, et al. Positron emission tomography and radioimmunotargeting general aspects. Acta Oncol 1999;38:335.
44. 86Y-DTPA-octreotide. Nucl Med Biol 1997;24:275.
45. Yoo J, Tang L, Perkins TA, Rowland DJ, Laforest R, Lewis, et al. Preparation of high specific activity (86)Y using a small biomedical cyclotron. Nucl Med Biol 2005;32:891.
46. Buchholz HG, Herzog H, Förster GJ, Reber H, Nickel O, Rösch F, et al. PET imaging with yttrium-86: comparison of phantom measurements acquired with different PET scanners before and after applying background subtraction. Eur J Nucl Med Mol Imaging 2003;30:716.
47. Walrand S, Jamar F, Mathieu L, De Camps J, Lonneux M, Sibomana M, et al. Quantitation in PET using isotopes emitting prompt single gammas: application to yttrium-86. Eur J Nucl Med Mol Imaging 2003;30:354.
48. Beattie BJ, Finn RD, Rowland DJ, Pentlow KS. Quantitative imaging of bromine-76 and yttrium-86 with PET: a method for the removal of spurious activity introduced by cascade gamma rays. Med Phys 2003;30:2410.
49. Kull T, Ruckgaber J, Weller R, Reske S, Glatting G. Quantitative imaging of yttrium-86 PET with the ECAT EXACT HR+ in 2D mode. Cancer Biother Radiopharm 2004;19:482.
50. Herzog H, Rosch F, Stocklin G, Lueders C, Qaim SM, Feinendegen LE. Measurement of pharmacokinetics of yttrium-86 radiopharmaceuticals with PET and radiation dose calculation of analogous yttrium-90 radiotherapeutics. J Nucl Med 1993;34:2222.
51. Forster GJ, Engelbach MJ, Brockmann JJ, Reber HJ, Buchholz HG, Macke HR, et al. Preliminary data on biodistribution and dosimetry for therapy planning of somatostatin receptor positive tumours: comparison of (86)Y-DOTATOC and (111)In-DTPA-octreotide. Eur J Nucl Med 2001;28:1743.
52. De Reuck J, Santens P, Strijckmans K, Lemahieu I, Lemahieu I. Cobalt-55 positron emission tomography in vascular dementia: significance of white matter changes. J Neurol Sci 2001;193:1.
53. 55Co-PET in stroke: relation to bloodflow, oxygen metabolism and gadolinium-MRI. J Neurol Sci 1999;171:11.
54. Jansen HM, Dierckx RA, Hew JM, Paans AM, Minderhoud JM, Korf J. Positron emission tomography in primary brain tumours using cobalt-55. Nucl Med Commun 1997;18:734.
55. Ellis BL, Sharma HL. Co, Fe and Ga chelates for cell labelling: a potential use in PET imaging? Nucl Med Commun 1999;20:1017.
56. Karanikas G, Schmaljohann J, Rodrigues M, Chehne F, Granegger S, Sinzinger H. Examination of co-complexes for radiolabeling of platelets in positron emission tomographic studies. Thromb Res 1999;94:111.
57. Jansen HM, Knollema S, van der Duin LV, Willemsen AT, Wiersma A, Franssen EJ, et al. Pharmacokinetics and dosimetry of cobalt-55 and cobalt-57. J Nucl Med 1996;37:2082.
58. 52mMn reactions from threshold up to 13.8 MeV. Radiochim Acta 2003;91:105.
59. Francois PE, Szur L. Use of iron-52 as a radioactive tracer. Nature 1958;182:1665.
60. Anger HO, Vandyke DC. Human bone marrow distribution shown in vivo by iron-52 and the positron scintillation camera. Science 1964;144:1587.
61. Silvester DJ, Sugden J. Production of carrier-free iron-52 for medical use. Nature 1966;210:1282.
62. Bailey DL, Young H, Bloomfield PM, Meikle SR, Glass D, Myers MJ, et al. ECAT ART-a continuously rotating PET camera: performance characteristics, initial clinical studies, and installation considerations in a nuclear medicine department. Eur J Nucl Med 1997;24:6.
63. Zweit J, Downey S, Sharma H. A method for the production of iron-52 with a very low iron-55 contamination. Int J Rad Appl Instrum 1988;39:1197-201.
64. Atcher RW, Friedman AM, Huizenga JR, Rayudu GV, Silverstein EA, Turner DA. Manganese-52m, a new short-lived, generator-produced radionuclide: a potential tracer for positron tomography. J Nucl Med 1980;21:565.
65. 52Fe in positron emission tomography. Appl Radiat Isot 1999;51(6):707-15, Dec.
66. 76Br-bromination of monoclonal antibodies using chloramine-T. Nucl Med Biol 1999;26:923.
67. Lovqvist A, Sundin A, Ahlstrom H, Carlsson J, Lundqvist H. Pharmacokinetics and experimental PET imaging of a bromine-76-labeled monoclonal anti-CEA antibody. J Nucl Med 1997;38:395-401.
68. 76Br-BFU as proliferation markers. J Nucl Med 2002;43:1688-98.
69. Meijs WE, Haisma HJ, Klok RP, Van Gog FB, Kievit E, Pinedo HM, et al. Zirconium-labeled monoclonal antibodies and their distribution in tumor-bearing nude mice. J Nucl Med 1997;38:112-8.
70. 90Y-labeled monoclonal antibodies in xenograft-bearing nude mice. J Nucl Med 2003;44:1663.
71. Mausner LF, Kolsky KL, Joshi V, Srivastava SC. Radionuclide development at BNL for nuclear medicine therapy. Appl Radiat Isot 1998;49:285-94.
72. DeNardo GL, DeNardo SJ, Meares CF, Kukis DL, Diril H, McCall MJ, et al. Pharmacokinetics of copper-67 conjugated Lym-1, a potential therapeutic radioimmunoconjugate, in mice and patients with lymphoma. Antibody Immunoconj Radiopharm 1991;4:777-85.
73. DeNardo GL, Kukis DL, Shen S, DeNardo DA, Meares CF, DeNardo SJ. 67-Cu versus 131-I-labeled Lym-1 antibody: comparative pharmacokinetics and dosimetry in patients with non-Hodgkin's lymphoma. Clin Cancer Res 1999;5:533-41.
74. O'Donnell RT, DeNardo GL, Kukis DL, Lamborn KR, Shen S, Yuan A, et al. A clinical trial of radioimmunotherapy with 67-Cu-2IT-BATLym- 1. J Nucl Med 1999;40:2014-20.
75. DeNardo SJ, DeNardo GL, Kukis DL, Shen S, Kroger LA, DeNardo DA, et al. 67Cu-2IT-BAT-Lym-1 pharmacokinetics, radiation dosimetry, toxicity and tumor regression in patients with lymphoma. J Nucl Med 1999;40:302-10.
76. Novak-Hofer I, Schubiger PA. Copper-67 as a therapeutic nuclide for radioimmunotherapy. Eur J Nucl Med Mol Imaging 2002;29:821-30.
77. McDevitt MR, Sgouros G, Finn RD, Humm JL, Jurcic JG, Larson SM, et al. Radioimmunotherapy with alpha-emitting nuclides. Eur J Nucl Med Mol Imaging 1998;25:1341-51.
78. Mulford DA, Scheinberg DA, Jurcic JG. The promise of targeted alpha-particle therapy. J Nucl Med 2005;46(Suppl 1):199S-204S.
79. Couturier O, Supiot S, Degraef-Mougin M, Faivre-Chauvet A, Carlier T, Chatal JF, et al. Cancer radioimmunotherapy with alpha-emitting nuclides. Eur J Nucl Med Mol Imaging 2005;32:601-14.
80. 211At in small volumes for evaluation of targeted radiotherapy in animal models. Nucl Med Biol 1995;22:45-54.
81. Welch MJ. Potential and pitfalls of therapy with alpha-particles. J Nucl Med 2005;46:1254-5.
82. Cherel M, Davodeau F, Kraeber-Bodere F, Chatal JF. Current status and perspectives in alpha radioimmunotherapy. Q J Nucl Med Mol Imaging 2006;50:322-9.
83. 64Cu. Nucl Instr and Meth B 2005;240:625.
84. Mausner LF, Hock JC. Target design consideration for isotope production with high intensity 200 MeV protons. Nucl Inst Meth A 1997;397:18.
85. Quaim SM. Nuclear data for medical applications: an overview. Radiochim Acta 2001;89:189.